1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
TSH Biopharm Corp. Ltd.

TSH Biopharm Corp. Ltd.

TTPEX:8432
54.70
TWD
-0.30
(-0.55%)
4.40EPS
14.54P/E
1.95BMarket Cap
Oct 29Next Earn
TSH Biopharm Corp. Ltd.
TPEX:8432
(Taipei Exchange)

Recent

price

54.70

P/E

ratio

14.54

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
9.12
21.43
17.81
15.55
14.63
13.38
12.83
12.66
13.43
13.22
11.66
10.8
19.3
21.12
29.06
34.81
32.33
Revenue per Share
1.81
5.48
4.22
2.87
1.94
2.16
3.68
1.69
1.5
2.22
1.6
1.23
1.61
1.61
2.95
3.63
3.5
Basic EPS, GAAP
2.22
5.45
-4.45
3.21
2.15
1.93
1.07
1.99
1.48
2.23
0.24
1.78
0.41
0.74
4.71
3.36
7.37
Free Cash Flow per Basic Share
- -
0.24
3.03
2.55
2.8
2
2.1
3.1
2.1
1.6
1.8
1.8
1.5
1.6
1.28
2.12
- -
Dividend per Share
14.56
19.3
26.7
27.02
26.16
35.48
37.77
29.86
29.19
29.3
29.33
28.22
29.58
28.85
36.25
37.57
36.85
Book Value per Share
14.38
19.17
26.62
26.22
25.52
34.98
37.36
29.52
28.92
29.08
29.17
28.13
27.91
27.45
28.76
30.03
29.3
Tangible Book Value per Share
24
31
34
38
38
38
38
38
38
38
38
38
38
38
38
38
38
Basic Weighted Avg Shares
217
660
597
597
562
514
492
486
516
508
448
413
741
811
1,116
1,337
1,243
Sales/Revenue/Turnover
23.78
30.37
27.22
22
13.77
7.16
6.26
14.58
10.88
11.07
16.57
13.43
9.32
7.61
15.29
16.41
17.32
Operating Margin (%)
1
3
6
9
9
8
7
6
6
10
10
10
22
23
29
27
27
Depreciation Expense
43
169
142
110
74
83
141
65
58
85
62
47
62
62
113
139
135
Net Income, GAAP
16.46
18.13
16.69
14.99
16.61
14.73
10.96
12.37
12.32
17.44
20.28
23.46
18.58
14.6
22.65
20
26.13
Effective Tax Rate (%)
19.88
25.55
23.69
18.46
13.25
16.14
28.67
13.36
11.21
16.81
13.75
11.39
8.35
7.64
10.14
10.42
10.83
Profit Margin (%)
485
523
898
885
793
857
936
862
796
747
845
834
937
980
1,096
1,196
1,145
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
- -
17
- -
10
7
5
LT Debt
493
654
1,025
1,038
1,005
1,362
1,450
1,147
1,121
1,125
1,126
1,084
1,213
1,266
1,623
1,718
1,677
Total Equity
16.59
27.35
15.79
9.93
6.27
2.64
1.94
4.72
4.72
4.1
5.17
3.79
4.52
4.24
8.85
10.09
9.36
Return on Invested Capital (%)
16.92
28.9
16.82
10.68
7.27
6.98
10.03
4.96
5.04
7.58
5.44
4.24
4.92
4.67
6.3
5.37
5.97
Return on Capital (%)
17.5
29.4
16.86
10.69
7.29
7
10.04
5
5.1
7.6
5.47
4.26
5.58
5.53
9.05
9.83
9.55
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
20
20
11
LT Borrowings
- -
- -
- -
LT Finance Leases
7
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
38
38
Market Capitalization
2,246
1,954
1,954

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,423
1,439
1,488
Cash, Cash Equivalents & STI
932
1,069
1,072
Accounts Receivable, Net
299
197
184
Inventories
156
138
146
Total Current Liabilities
227
223
344
Payables & Accruals
- -
- -
- -
ST Debt
20
20
11
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.03%
9.31%
5.83%
Free Cash Flow
113.23%
230.97%
-28.67%
Net Income, GAAP
13.88%
22.73%
23.14%
Sales/Revenue/Turnover
12.57%
27.67%
19.79%
Total Cash Common Dividend
- -
- -
65.62%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
200
236
389
291
1,116
2025
287
269
- -
358
1,337
2026
286
331
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.07
0.37
1.26
0.25
2.95
2025
0.79
0.68
- -
0.62
3.63
2026
1.01
1.19
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.28
2025
- -
- -
- -
- -
2.12
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
TSH Biopharm Corporation Limited is a Taiwan-based specialty pharmaceutical company primarily engaged in the development, manufacturing, and marketing of branded and generic pharmaceutical products. The company focuses on therapeutic areas including cardiovascular diseases, central nervous system disorders, gastrointestinal diseases, and autoimmune conditions. Its core product portfolio includes cardiovascular drugs such as Amtrel (compound anti-hypertensives), Rytmonorm (arrhythmia treatment), Linicor and Cretrol (lipid-lowering agents), gastrointestinal drugs like Mopride for functional dyspepsia and Catilon for irritable bowel syndrome, as well as immunosuppressive drugs including Aleviatin, Lonine (for rheumatoid arthritis and osteoarthritis), and Lacoxa SR. In addition to pharmaceuticals, TSH Biopharm offers precision medicine services such as next-generation sequencing genetic testing and cancer diagnostics. Founded in 2010 and headquartered in Taipei, Taiwan, TSH Biopharm operates mainly within the Taiwanese domestic market but has expanded its product registrations and marketing to other Asian regions including Thailand, Myanmar, Hong Kong, and Macau. It is a subsidiary of TTY Biopharm Company Limited and actively pursues strategic investments in biotechnology firms like CYB Biotechnology and Top Pharma & Bio-Tech, enhancing its product portfolio and market reach in preventive medicine, vaccines, and elderly care products. Notable recent developments include the approval and launch of TYRVAYA® for dry eye disease nasal spray by the Taiwan FDA in 2024, marking a significant innovation in TSH's product offerings. The company also expanded its geographic footprint by officially launching the Lonine drug in Macau in 2025. Additionally, TSH Biopharm emphasizes corporate sustainability, having established a Sustainability Development Committee in 2022 and receiving recognition for its environmental and social initiatives at the 2025 Asia Responsible Enterprise Awards. The company continues strategic collaborations with partners in Korea and Spain to extend its cancer diagnostics and orthopedic product lines, and it actively engages in community health and sustainability programs in Taiwan. TSH Biopharm’s integrated approach combines pharmaceutical manufacturing, biotechnology research, precision medical testing, and market expansion across Asia, consolidating its position as a leading player in specialty pharmaceuticals focused on chronic and autoimmune diseases. The company maintains a diversified portfolio aimed at improving patient quality of life through innovative therapies and precision medicine solutions.